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Abstract
Background and purpose—We recently showed that lapatinib, an EGFR/HER2 inhibitor,
radiosensitized breast cancer cells of the basal and HER2+ subtypes. The purpose of this study was
to identify the downstream signaling pathways responsible for lapatinib-mediated radiosensitization
in breast cancer.
Materials and methods—Response of EGFR downstream signaling pathways were assessed by
western blot and clonogenic cell survival assays in breast tumor cells after irradiation (5 Gy),
lapatinib, CI-1040, or combined treatment.
Results—In SUM102 cells, an EGFR+ basal breast cancer cell line, exposure to ionizing radiation
elicited strong activation of ERK1/2 and JNK, which was blocked by lapatinib, and weak/no
activation of p38, AKT or STAT3. Direct inhibition of MEK1 with CI-1040 resulted in 95%
inhibition of surviving colonies when combined with radiation while inhibition of JNK with
SP600125 had no effect. Lapatinib-mediated radiosensitization of SUM102 cells was completely
abrogated with expression of constitutively active Raf. Treatment of lapatinib-resistant SUM185
cells with CI-1040 restored radiosensitization with 45% fewer surviving colonies when combined
with radiation.
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Conclusions—These data suggest that radiosensitization by lapatinib is mediated largely through
inhibition of MEK/ERK and that direct inhibition of this pathway may provide an additional avenue
of radiosensitization in EGFR+ or HER2+ breast cancers.
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Introduction
The use of pharmacological compounds targeting specific intracellular signaling pathways to
sensitize tumor cells to ionizing radiation can improve the radiotherapeutic index resulting in
improved patient outcomes [1]. Importantly, using a monoclonal antibody against EGFR which
could provide a multifactorial response including antibody dependent cytotoxicity, a landmark
Phase III randomized trial reported disease-free and overall survival advantages for HNSCC
patients when treated with cetuximab in combination with radiation in comparison to treatment
with radiation alone [2].
Breast cancer arises from one of two epithelial cell populations resulting in breast cancers of
basal- or luminal-origin with basal subtypes conferring a worse prognosis [3-6]. At least 50%
of basal-like breast cancers are known to express EGFR as determined by IHC [7] and we
recently showed that breast tumor cell lines of the basal-subtype (SUM102 and SUM149),
which express elevated levels of EGFR and normal levels of HER2, are not only growth
impaired and radiosensitized by treatment with the dual EGFR/HER2 inhibitor lapatinib and
the EGFR-specific inhibitor, gefitinib, but also show relatively higher sensitivity to gefitinib
than breast cancer cells derived from luminal origin [8,9]. Given that EGFR expression
correlates with radioresistance [10,11] and that EGFR can signal to a variety of downstream
signaling pathways including MEK>ERK, PI3K>AKT, STAT, p38 and JNK [12,13],
identification of the downstream signaling pathways that mediate radiosensitization by EGFR
or EGFR/HER2 inhibitors could reveal novel alternative radiosensitizers. In this study, we
evaluated the downstream signaling pathways responsible for lapatinib-mediated
radiosensitization in breast cancer cells of the basal subtype and demonstrate that
radiosensitization is mediated primarily through inhibition of the Raf>MEK>ERK mitogen-
activated protein kinase cascade. In addition, we demonstrate that radiosensitization of a
lapatinib-resistant breast cancer cell line of luminal B subtype can be sensitized by inhibition
of the Raf>MEK>ERK pathway. These studies reveal important mechanisms of the signaling
pathways that mediate radiosensitization by an EGFR/HER2 inhibitor in breast cancer and
suggest that future studies are warranted to evaluate inhibitors of the Raf>MEK>ERK pathway
as radiosensitizers in breast cancer.
Materials & Methods
Reagents
Lapatinib, a dual EGFR/HER2 kinase inhibitor (provided by GlaxoSmithKline), CI-1040, a
MEKI inhibitor (provided by Pfizer), and SP600125, a JNK inhibitor II (purchased from
Calbiochem) were dissolved with dimethyl sulfoxide (DMSO), aliquoted and stored frozen at
−20°C. All cell culture reagents were from GIBCO (Carlsbad, CA).
Cell lines and constructs
SUM102 and SUM185 cells were cultured as previously described [8]. Constitutively active
c-Raf is an N-terminal truncation mutant referred to as c-Raf(22W) and was provided in the
retroviral vector pBabe by Channing Der (University of North Carolina). SUM102 cells stably
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expressing pBabepuro/c-Raf-(22W) or pBabepuro alone were generated by retroviral infection
with virus produced utilizing the triple transfection method in 293T cells as described by the
manufacturer (Stratagene). Forty-eight h post-infection, cells were selected with puromycin (1
μg/ml), selected and used en masse.
Western blot analyses
Cells were plated and allowed to adhere in complete media for 24 h and treated with drug or
equal amounts of vehicle control (DMSO) for 2 h before being irradiated with 5 Gy and protein
lysates harvested with lysis buffer as previously described [8]. Proteins (30 μg) were separated
over 12% sodium dodecyl sulphate (SDS)/poly-acrylamide gels and electrophoretically
transferred to polyvinyl difluoride (PVDF), blocked, and probed with anti-phospho-ERK1/2
(T202/Y204, #9101), anti-total ERK1/2 (#9102), anti-phospho AKT (S473, #9271), anti-total
AKT (#9272), anti-phospho JNK (T183/Y185, #9251), anti-total JNK (#9252), anti-phospho-
p38 MAPK (T180/Y182, #9211), anti-total p38 MAPK (#9212), anti-phospho-STAT3 (Y705,
#9131), anti-total STAT3 (#9132), all from Cell Signaling Technology, anti-β-actin (#A5316;
Sigma), or anti-Raf1 (#sc-133; Santa Cruz Biotechnology). The secondary antibodies used
were horseradish peroxidase–conjugated (Cell Signaling Technology) and visualization by
enhanced chemiluminescence (Amersham). Immunoprecipitation of EGFR was with rabbit
anti-EGFR (Ab22) and western blot with anti-phospho-tyrosine RC20 (BD Transduction
Laboratories) as previously described [8].
Colony-forming assays
Cells were plated at low density overnight in complete media and treated for 2 h with drug or
equal amounts of DMSO vehicle alone (control), irradiated or sham-irradiated with graded,
single doses from a 137Cs irradiator at a dose rate of 158 cGy/min. In all conditions, the culture
medium was changed 2 h post-irradiation to complete medium without drug. After 2 – 4 weeks
of incubation, the samples were fixed counted as described [8]. The surviving fraction [number
of colonies formed/number of cells plated x plating efficiency] was calculated from the number
of colonies formed in the drug-treated, irradiated dishes compared with the number formed in
the drug-treated, unirradiated control and significance as defined by p<0.001 by unpaired t-
test indicated (*). The clonogenic survival curves were fitted to a linear-quadratic model
(SF=e−[α * D + β * D2]) using GraphPad Prism 5.0 according to a least squares fit, weighted to
minimize the relative distances squared, and compared using the extra sum-of-squares F test.
Each point represents the mean surviving fraction from at least three dishes; error bars represent
the standard deviation.
Results
Radiation Induced Activation of ERK1/2 and JNK are Blocked by Lapatinib
Basal-like breast cancer represents 16% of all breast cancers and patients with this subtype
face a poor prognosis (reviewed in [14]). SUM102 cells are breast cancer cells of the basal-
subtype that overexpress EGFR. The purpose of this study was to identify the downstream
signaling pathways responsible for lapatinib-mediated radiosensitization in breast cancer using
the SUM102 cells as a model system. We first verified lapatinib could block EGFR activation
in SUM102 cells stimulated with EGF (Supp. Fig. 1).
Next, to identify which pathways are activated downstream of EGFR in response to radiation,
we assessed the changes in levels of activated p-ERK1/2, p-AKT, p-STAT3, p-p38, and p-JNK
in SUM102 cells treated with 5Gy radiation. As shown in Fig. 1, SUM102 cells showed an
initial decrease in levels of activated p-ERK1/2 and p-JNK at 15 and 30 min post-irradiation
followed by a robust activation at 60 and 90 min. In contrast, while activated p-p38 was
similarly inhibited at 15 post-irradiation, expression levels similar to that at baseline were
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restored by 60 min. In addition, no significant change in either p-STAT3 or p-AKT was seen
in response to radiation.
To determine whether the radiation-induced activation of ERK1/2 and JNK are mediated by
upstream activation of EGFR, SUM102 cells were pretreated either with the dual EGFR/HER2
kinase inhibitor lapatinib or vehicle for 2 h prior to radiation treatment. As shown in Fig. 1,
inhibition of EGFR/HER2 by lapatinib abolished radiation-induced activation of p-ERK1/2,
and p-JNK while p-p38, p-STAT3 and p-AKT were unchanged. These data demonstrate that
in basal breast cancer cells with overexpression of EGFR, response to ionizing radiation
involves EGFR-mediated activation of ERK1/2 and JNK.
Lapatinib-Mediated Radiosensitization is Mediated Primarily Through Inhibition of
MEK1/2>ERK1/2
Since lapatinib can inhibit activation of ERK and JNK in response to radiation we sought to
determine whether direct inhibition of ERK1/2 or JNK could likewise radiosensitize cells. To
determine this, SUM102 cells were pretreated for 2 hr with vehicle (DMSO) alone or specific
inhibitors against MEK1 (CI-1040) or JNK (SP600125) prior to irradiation at 5 Gy and
percentage of surviving colonies compared among treatment groups. As shown in Fig. 2,
inhibition of MEK1 with CI-1040 inhibited colony formation by 95% compared to control
DMSO-treated cells while JNK inhibition with SP600125 showed no ability to radiosensitize
using drug doses that effectively inhibited, at least in part, activation of ERK1/2 and JNK,
respectively, in response to irradiation. These data suggest that EGFR-mediated
radiosensitization is mediated largely through inhibition of MEK>ERK.
Constitutively Active RAF Abrogates Lapatinib-Mediated Radiosensitization
If lapatinib-mediated radiosensitization of SUM102 cells is mediated primarily by inhibition
of MEK1/2>ERK1/2, then constitutive activation of the Raf>MEK>ERK pathway should
block lapatinib-mediated radiosensitization. To test this, stable cell lines of SUM102 cells were
first generated that express either empty vector or constitutively active Raf. As expected, the
cells expressing Raf exhibited high levels of activated p-ERK1/2 and were completely resistant
to lapatinib-mediated inhibition of p-ERK1/2 while cells expressing vector alone exhibited low
levels of active p-ERK1/2 which could be abolished with lapatinib treatment (Fig. 3). We next
compared the ability of the cells expressing Raf to block lapatinib-mediated radiosensitization
of the SUM102 cells over a dose range of 0 – 7 Gy. As shown in Fig. 3, vector expressing
SUM102 cells were radiosensitized when pretreated with lapatinib compared to DMSO
vehicle. Interestingly, SUM102 cells expressing Raf were not only more resistant to irradiation
compared to vector expressing cells with resistance reaching 7.5-fold at 7 Gy, but also
completely insensitive to radiosensitization by lapatinib. That activated Raf can confer
radioresistance is consistent with our previous studies showing Raf-mediated resistance to
irradiation in rat intestinal epithelial cells [15]. Thus, constitutive activation of the
Raf>MEK>ERK pathway alone is sufficient to block lapatinib-mediated radiosensitization
suggesting that the Raf>MEK>ERK pathway plays a major role in EGFR-mediated
radioresistance.
Lapatinib-Resistant SUM185 Cells are Radiosensitized by Inhibition of MEK
SUM185 cells are a breast tumor cell line of the luminal B subtype that we previously
demonstrated to express elevated levels of HER2 with normal levels of EGFR which are
insensitive to the antiproliferative and radiosensitizing effects of lapatinib [8,16]. We reasoned
that insensitivity of SUM185 cells to lapatinib might be due to additional mutations or other
signaling aberrancies that, like EGFR, also activate the Raf>MEK>ERK pathway resulting in
lapatinib resistance. We hypothesized that if radiosensitization is mediated primarily by
inhibition of the Raf>MEK>ERK pathway as in the SUM102 cells, then direct inhibition of
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MEK in the SUM185 cells should restore radiosensitization. To test this hypothesis, SUM185
cells were pretreated with lapatinib or the MEK1 inhibitor (CI-1040) prior to irradiation at 5
Gy and percentage of surviving colonies compared to cells pretreated with DMSO alone. As
shown in Fig. 4, while SUM185 cells showed no radiosensitization to lapatinib, inhibition of
the MEK>ERK pathway with CI-1040, as demonstrated by diminished levels of activated p-
ERK1/2, effectively restored radiosensitization. Collectively, these data demonstrate that
activation of the Raf>MEK>ERK pathway by EGFR/HER2 and alternative activators plays
an important role in the response to radiation such that direct inhibition of the Raf>MEK>ERK
pathway could provide an additional avenue of therapeutic radiosensitization in breast cancer
tumors that stain positive histochemically for p-ERK1/2.
Discussion
We previously demonstrated that lapatinib-mediated inhibition of EGFR in breast cancer cell
lines of the basal-subtype resulted in inhibition of proliferation and radiosensitization [8]. In
the present study we show that the primary downstream signaling pathway responsible for
lapatinib-mediated radiosensitization is through inhibition of the Raf>MEK>ERK mitogen-
activated protein kinase cascade. We demonstrate that direct inhibition MEK alone is sufficient
to radiosensitize basal breast cancer cells and luminal B breast cancer cells which are lapatinib-
resistant. Thus, we hypothesize that inhibition of the Raf>MEK>ERK pathway may represent
an alternative therapeutic approach to radiosensitize breast cancers with elevated activation of
and “addiction” to this pathway.
Preclinical studies have shown effective radiosensitization of a wide array of different cancer
cell lines and xenografts with a variety of inhibitors that target either EGFR alone (e.g.,
cetuximab, erlotinib) or multiple EGFR-family members (e.g., lapatinib) [reviewed in
([17-20]. Responses have been impressively consistent between studies, with
radiosensitization accompanied by inhibition of proliferation, cell cycle arrest, decreased
angiogenesis/VEGF expression, and increased apoptosis in most studies [8,21-26]. The
improved clinical outcome demonstrated in HNSCC patients treated with cetuximab, a
monoclonal antibody against EGFR, in combination with radiation in comparison to treatment
with radiation alone, provided the first definitive evidence of radiosensitization by EGFR
inhibitors supporting similar efforts in other cancer subtypes that exhibit activation of the
EGFR family of receptors [2]. In addition, early clinical trials with inhibitors of the EGFR
family of receptors as radiosensitizers has shown promise [reviewed in [27]). However, given
that EGFR can signal to a variety of downstream effectors, the precise mechanism of
radiosensitization by EGFR blockade has not been fully elucidated. The purpose of our study
was to identify those downstream signaling pathways important in mediating radiosensitization
by lapatinib in breast cancers.
Previous studies have demonstrated a clear role of EGFR/HER2 downstream signaling in
response to radiation [20]. There are several studies that support a role for PI3K>AKT
signaling, an important EGFR/HER2 downstream signaling effector, in radioresistance. In
radioresistant lung cancer cell lines, constitutive AKT activation was frequently observed and
PI3K inhibitors showed ability to radiosensitize [28]. In a radioresistant HNSCC cell line,
inhibition of EGFR and direct inhibition of the PI3K>AKT pathway resulted in
radiosensitization, suggesting that aberrant EGFR activation of PI3K>AKT was responsible
for radioresistance [29]. Toulany et al. showed radioresistance is mediated by AKT in K-ras
mutant breast and lung cancer cells through Ras-mediated autocrine signaling to EGFR [30,
31]. Our previous findings of Ras-mediated radioresistance also implicated PI3K>AKT
signaling as PI3K inhibitors reversed, at least in part, Ras-mediated radioresistance which could
also be abrogated with EGFR inhibitors [15,32]. Interestingly, our studies here of SUM102
cells showed no change in levels of activated AKT either in the presence or absence of lapatinib
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in response to radiation suggesting that the PI3K>AKT pathway does not play an important
role either in the response to radiation or mediate the radiosensitizing effects of lapatinib in
basal breast cancer.
We and others previously showed a link between EGFR activation of the Raf>MEK>ERK
pathway in response to radiation and the ability of constitutively active Raf to confer
radioresistance in other cell types [15,33,34]. Consistent with these studies, our findings here
in SUM102 cells expressing constitutively active Raf demonstrated a 7.5-fold increase in
surviving colonies after radiation treatment compared to control cells supporting a role for the
Raf>MEK>ERK pathway in conferring radioresistance in basal breast cancer. Importantly, we
found that SUM102 cells elicited strong activation of ERK1/2 in response to irradiation which
could be blocked by pretreatment with lapatinib. These data show that EGFR-mediated
activation of the downstream Raf>MEK>ERK pathway plays an important role in response to
radiation. This was supported by additional studies whereby MEK was directly inhibited with
CI-1040 with a resulting 95% inhibition of surviving colonies when combined with radiation.
Our findings showing the importance of Raf>MEK>ERK signaling in breast cancers of the
basal subtype are consistent with those by Mirzoeva et.al. who recently compared susceptibility
among breast cancer subtypes and found the basal-subtype to be the most sensitive to MEK
inhibitors [35].
While JNK has previously been implicated as a promoter of apoptosis in response to irradiation
and other radiosensitizers in some cancer cells [36-38], our studies do not support its role in
mediating radioresistance in basal breast cancer. While SUM102 cells treated with ionizing
radiation elicited activation of JNK which was blocked by lapatinib, treatment with the JNK
inhibitor SP600125 resulted in no radiosensitization. However, the lack of radiosensitization
observed with SP600125 may be reflective of a lack of drug potency and specificity of
SP600125 rather than a lack of an important role of JNK in the radioresponse [39].
Little is known about the role, if any, of STAT signaling in response to radiation while STATs
have been shown to be important regulators of breast cancer cell proliferation and survival
[40]. A recent study with a hepatoma cell line showed an increase in STAT3 expression with
increasing radiation dose [41]. A separate study in prostate cancer cells found an association
of increased pSTAT1 levels with radioresistant cell lines [42]. Our studies here showed little
change in activated p-STAT3 levels in response to irradiation suggesting that lapatinib-
mediated radiosensitization is likely not mediated by inhibition of STAT3.
Lastly, the molecular underpinnings that confer resistance to EGFR/HER2 inhibitors are poorly
understood. While EGFR/HER2 inhibitors remain an attractive therapy option, accurate
molecular predictors of response are lacking along with an understanding of the mechanisms
that support the development of resistance [43-45]. Oncogenic addiction is a proposed
mechanism by which a tumor cell becomes largely reliant on a primary activated oncogene
[46]. It is thought that therapeutic resistance can develop to the primary oncogene if a secondary
oncogenic stimulus can activate the same downstream pathway(s) [47]. In this sense, tumor
cells can respond to inhibition of an upstream activator of a pathway to which they are
“addicted” by “switch-hitting” to maintain activation of the pathway to which they are
“addicted”. For e.g., in NSCLC and HNSCC cells, resistance to the anti-EGFR antibody,
cetuximab, is associated with increased expression of and a switching from EGFR to HER2,
HER3 and cMET with resultant maintenance of addiction to activation of ERK1/2 and AKT
[48]. In a separate study of NSCLC cells, lack of response to cetuximab also correlated with
maintenance of pathway addiction with lack of observed cetuximab-mediated inhibition of
either ERK or AKT phosphorylation [49]. In breast cancer, resistance to Trastuzumab, a
monoclonal antibody directed against HER2, can be overcome by treatment with lapatinib
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reportedly through its ability to inhibit HER2-mediated activation of and switching to the
insulin-like growth factor I receptor [50].
In our studies, we previously showed that despite effective inhibition of HER2, lapatinib was
ineffective at inhibiting ERK1/2 and AKT activation in SUM185 cells which were completely
resistant to growth inhibition or radiosensitization by lapatinib [8]. In our present study we
demonstrated that direct inhibition of MEK with CI-1040 blocked activation of ERK1/2 and
effectively radiosensitized the lapatinib-resistant SUM185 cells with 45% fewer colonies
surviving radiation plus CI-1040 treatment relative to control cells treated with radiation alone.
While the ability to radiosensitize SUM185 cells with CI-1040 was not as robust as that seen
for SUM102 cells, the differences in the mechanisms by which MEK1/2>ERK1/2 become
activated through various positive regulators including receptor and non-receptor tyrosine
kinases, integrins, growth factors, cytokines, GPCRs and direct mutations in Ras or Raf
combined with loss of negative regulators (e.g. MAP kinase phosphatases), along with the
magnitude and duration of MEK1/2>ERK1/2 activation [reviewed in [51]], and how dependent
a tumor cell becomes to an oncogenic signaling pathway [reviewed in [52]] could account for
the differences in CI-1040 sensitivity observed in these cell lines. Here, SUM102 cells have
relatively higher ERK1/2 activation than SUM185 cells and might be more “addicted” to
MEK1/2>ERK1/2 signaling and thus more sensitive to inhibitors of this pathway. While we
have not identified the alternative upstream oncogenic signal responsible for continued
activation of ERK1/2 in the presence of lapatinib in the SUM185 cells, these cells represent a
model system in which to study resistance and demonstrate that identification of the pathway
(s) to which a tumor cell has become addicted, in this case the MEK1/2>ERK1/2 MAPK
pathway, can provide additional therapeutic options as demonstrated here with CI-1040.
Collectively, our study supports a model in EGFR+ basal breast cancers whereby EGFR-
mediated activation of the Raf>MEK>ERK pathway plays a vital role in response to radiation
with lapatinib or CI-1040-mediated blockade of this response providing radiosensitization. In
addition, inactivation of the Raf>MEK>ERK pathway with MEK inhibitors could provide an
alternative radiosensitizing treatment option in other breast cancers that are “addicted” to this
pathway. Our data support further studies to evaluate the ability of inhibitors of the
Raf>MEK>ERK pathway to radiosensitize breast cancers. A major challenge in EGFR-
targeted therapies, as in most cancer therapies, is to find new ways to predict and overcome
the development of resistance. The clinical evaluation of Raf>MEK>ERK “addiction” and the
therapeutic use of efficacious MEK inhibitors could provide a solution to that challenge.
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FIG. 1. The dual EGFR/HER2 kinase inhibitor lapatinib blocks radiation-induced activation of
ERK1/2 and JNK in SUM102 cells
SUM102 cells were grown to 80% confluence in complete medium and lapatinib (2.5 μM) or
DMSO vehicle control added 2 h prior to irradiation at 5 Gy. Protein lysates were collected
from 0-90 min after irradiation and western blot analyses performed with the indicated
antibodies.
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FIG. 2. Radiosensitization by lapatinib is mediated primarily through inhibition of MEK
(A) SUM102 cells were grown to 80% confluence in complete medium and treated with CI1040
(1 μM), SP600125 (20 μM) or vehicle (DMSO) 2 h prior to irradiation at 5 Gy. Protein lysates
were collected at 0-90 min after irradiation and western blot analyses performed with the
indicated antibodies. (B) SUM102 cells were treated with SP600125 (20 μM), CI-1040 (1
μM), lapatinib (2.5 μM ) or vehicle (DMSO) 2 h prior to irradiation at 5 Gy and the media
replaced without drug and colonies counted after 2 weeks. Surviving fractions of each treatment
were normalized to cells treated with radiation alone (5 Gy). * indicates p<0.001 by unpaired
t-test.
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FIG. 3. Constitutively active Raf abrogates lapatinib-mediated radiosensitization
(A) SUM102 cells with stable expression of constitutively active Raf were generated by
retroviral infection with constructs expressing Raf or empty vector as control and protein
lysates compared by western blot analysis with anti-Raf or anti-actin antibodies. (B) SUM102
cells expressing Raf or vector were treated with increasing amounts of lapatinib for 2 h, protein
lysates collected and p-ERK1/2 levels compared by western blot analysis. (C) SUM102 cells
expressing Raf or vector alone were plated at low density and allowed to adhere for 24 h. Two
h prior to irradiation, cells were exposed to lapatinib (2.5 μM) or DMSO (control) and treated
with single, graded doses of radiation as indicated and the media replaced without drug 2 h
post-irradiation. Colonies of >25 cells were counted approximately 2 weeks after treatment
and clonogenic surviving fractions generated with each point representing the mean surviving
fraction calculated from three independent experiments done in triplicate for each treatment
condition; error bars represent the standard deviation.
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FIG. 4. Lapatinib-resistant SUM185 cells are radiosensitized by MEK inhibition
(A) SUM185 cells were grown to 80% confluence in complete medium and CI-1040 (1 μM)
or DMSO vehicle control added 2 h prior to irradiation at 5 Gy. Protein lysates were collected
from 0-90 min after irradiation and western blot analyses performed with anti-pERK1/2 or
anti-ERK1/2 as a loading control. (B) SUM185 cells were treated with CI-1040 (1 μM),
lapatinib (2.5 μM ) or vehicle (DMSO) 2 h prior to irradiation at 5 Gy and the media replaced
without drug 2 h post-irradiation and colonies >50 cells counted after 2 weeks. Surviving
fractions for each drug were normalized to cells treated with radiation alone (5 Gy). * indicates
p<0.001 by unpaired t-test.
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